These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38285739)

  • 1. LDL-C-Lowering Therapies for Adults and Children With Homozygous Familial Hypercholesterolemia: Challenges and Successes.
    Santos RD; Cuchel M
    Circulation; 2024 Jan; 149(5):363-366. PubMed ID: 38285739
    [No Abstract]   [Full Text] [Related]  

  • 2. Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia.
    Wiegman A; Greber-Platzer S; Ali S; Reijman MD; Brinton EA; Charng MJ; Srinivasan S; Baker-Smith C; Baum S; Brothers JA; Hartz J; Moriarty PM; Mendell J; Bihorel S; Banerjee P; George RT; Hirshberg B; Pordy R
    Circulation; 2024 Jan; 149(5):343-353. PubMed ID: 37860863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gradual dose Titration of Lomitapide may Prevent Therapeutic Delays in Patients with Homozygous Familial Hypercholesterolemia.
    Harada-Shiba M; Koezuka R; Makino H; Ogura M
    J Atheroscler Thromb; 2023 Feb; 30(2):203-205. PubMed ID: 35732425
    [No Abstract]   [Full Text] [Related]  

  • 4. The treatment of heterozygous familial hypercholesterolemia - a local perspective.
    Bułdak Ł
    Endokrynol Pol; 2021; 72(3):189-190. PubMed ID: 34292576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.
    Leipold R; Raal F; Ishak J; Hovingh K; Phillips H
    Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evinacumab for Homozygous Familial Hypercholesterolemia.
    Raal FJ; Rosenson RS; Reeskamp LF; Hovingh GK; Kastelein JJP; Rubba P; Ali S; Banerjee P; Chan KC; Gipe DA; Khilla N; Pordy R; Weinreich DM; Yancopoulos GD; Zhang Y; Gaudet D;
    N Engl J Med; 2020 Aug; 383(8):711-720. PubMed ID: 32813947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries.
    Arca M; Celant S; Olimpieri PP; Colatrella A; Tomassini L; D'Erasmo L; Averna M; Zambon A; Catapano AL; Russo P
    J Am Heart Assoc; 2023 Nov; 12(21):e026550. PubMed ID: 37850449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
    Bell DA; Hooper AJ; Watts GF; Burnett JR
    Vasc Health Risk Manag; 2012; 8():651-9. PubMed ID: 23226021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry.
    Cuchel M; Lee PC; Hudgins LC; Duell PB; Ahmad Z; Baum SJ; Linton MF; de Ferranti SD; Ballantyne CM; Larry JA; Hemphill LC; Kindt I; Gidding SS; Martin SS; Moriarty PM; Thompson PP; Underberg JA; Guyton JR; Andersen RL; Whellan DJ; Benuck I; Kane JP; Myers K; Howard W; Staszak D; Jamison A; Card MC; Bourbon M; Chora JR; Rader DJ; Knowles JW; Wilemon K; McGowan MP
    J Am Heart Assoc; 2023 May; 12(9):e029175. PubMed ID: 37119068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Understanding the efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia.
    Pirillo A; Catapano AL
    Eur J Prev Cardiol; 2022 May; 29(5):829-831. PubMed ID: 35148370
    [No Abstract]   [Full Text] [Related]  

  • 11. Editorial commentary: Exciting new therapies for familial hypercholesterolemia, but we can also make better use of some old ones.
    Walsh JP
    Trends Cardiovasc Med; 2023 Apr; 33(3):180-181. PubMed ID: 35091044
    [No Abstract]   [Full Text] [Related]  

  • 12. Novel therapies for familial hypercholesterolemia.
    Mohamed F; Seedat F; Raal FJ
    Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):188-195. PubMed ID: 33278127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evinacumab-dgnb (Evkeeza-REGN1500), A Novel Lipid-Lowering Therapy for Homozygous Familial Hypercholesterolemia.
    White RT; Sankey KH; Nawarskas JJ
    Cardiol Rev; 2024 Mar-Apr 01; 32(2):180-185. PubMed ID: 37071085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Identifying possible homozygous familial hypercholesterolemia patients: an Italian experts' opinion].
    Bilato C; Zambon A; Pisciotta L; Citroni N; Carubbi F; Zambon S; Zenti MG; Vinci P; Biolo G; Bonomo K; Egalini F; Passaro A; Nascimbeni F; Negri E; D'Addato S; Averna M; Arca M; Oliva F; Colivicchi F; Catapano A
    G Ital Cardiol (Rome); 2023 Jan; 24(1):5-10. PubMed ID: 36573504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New algorithms for treating homozygous familial hypercholesterolemia.
    Tromp TR; Cuchel M
    Curr Opin Lipidol; 2022 Dec; 33(6):326-335. PubMed ID: 36206078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Familial hypercholesterolemia from children to adults.
    Ose L
    Cardiovasc Drugs Ther; 2002 Jul; 16(4):289-93. PubMed ID: 12652097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homozygous Familial Hypercholesterolaemia International Clinical Collaboration (HICC) registry: Levelling up access to treatment urgently needed.
    Stock JK
    Atherosclerosis; 2022 Apr; 346():84-85. PubMed ID: 35246317
    [No Abstract]   [Full Text] [Related]  

  • 18. New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia.
    Cesaro A; Fimiani F; Gragnano F; Moscarella E; Schiavo A; Vergara A; Akioyamen L; D'Erasmo L; Averna M; Arca M; Calabrò P
    Heart Fail Clin; 2022 Jan; 18(1):177-188. PubMed ID: 34776078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial hypercholesterolemia treatments: Guidelines and new therapies.
    Raal FJ; Hovingh GK; Catapano AL
    Atherosclerosis; 2018 Oct; 277():483-492. PubMed ID: 30270089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rescue therapy with PCSK9 inhibitors for patients with delayed diagnosis of heterozygous familial hypercholesterolemia: Redressing the balance of missed opportunities.
    Vuorio A; Watts GF; Kovanen PT
    J Clin Lipidol; 2016; 10(5):1278-9. PubMed ID: 27678448
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.